- Home
- Results news
- Transchem
- Q2 FY27 results
Transchem Q2 FY27 results: net profit ₹2.05 crore
Transchem Limited reported consolidated revenue of ₹0.93 crore and a net profit of ₹2.05 crore for Q2 FY27, with an EBITDA margin of -129.1%. The company reported no exceptional item for the quarter, while the standalone result showed revenue of ₹0 crore and profit before tax of ₹0.68 crore.
Key points
- Consolidated Q2 FY27 revenue was ₹0.93 crore, with other income of ₹4.14 crore and total income of ₹4.14 crore.
- Consolidated Q2 FY27 EBITDA was ₹1.20 crore, with an EBITDA margin of -129.1%.
- Consolidated Q2 FY27 profit before tax was ₹2.86 crore, while net profit was ₹2.05 crore and basic EPS was ₹1.68.
- As of 30 September 2026, total assets were ₹226.21 crore, total equity was ₹204.35 crore, borrowings were ₹0 crore and cash was ₹75.05 crore.
- Among 65 Pharmaceuticals peers compared, the median revenue growth was 18.9%; 43 of 60 peers with profit data reported higher profit.
How did Transchem perform in Q2 FY27?
Transchem Limited reported consolidated revenue of ₹0.93 crore for Q2 FY27, other income of ₹4.14 crore, total income of ₹4.14 crore and total expenses of ₹2.21 crore. The company reported EBITDA of ₹1.20 crore and an EBITDA margin of -129.1%. No exceptional item was reported. The board approved the unaudited standalone and consolidated results for the quarter and half-year ended 30 September 2026 on 4 November 2026.
On a consolidated basis, profit before tax was ₹2.86 crore for Q2 FY27, tax expense was ₹0.81 crore and net profit attributable to owners was ₹2.05 crore. Basic EPS was ₹1.68. The available data do not provide consolidated revenue, EBITDA, profit or EPS comparisons with the year-ago quarter or the previous quarter. Standalone figures reported revenue of ₹0 crore and profit before tax of ₹0.68 crore for the quarter.
| ₹ crore | Q2 FY27 |
|---|---|
| Revenue from operations | 0.93 |
| Other income | 4.14 |
| Total expenses | 2.21 |
| EBITDA | −1.20 |
| EBITDA margin | -129.1% |
| Profit before tax | 2.86 |
| Tax | 0.81 |
| Net profit | 2.05 |
| EPS (₹) | 1.68 |
EBITDA here is revenue from operations less operating costs (total expenses excluding finance costs and depreciation): before other income and exceptional items. Growth is shown only when both figures are positive. Source: Company's results filing (XBRL).
What do the balance sheet and cash flow show?
As of 30 September 2026, Transchem reported total assets of ₹226.21 crore and total equity of ₹204.35 crore on a consolidated basis. Borrowings were ₹0 crore, while cash was ₹75.05 crore. The available data do not provide the corresponding balance-sheet figures for the previous balance-sheet date.
For H1 FY27, consolidated cash flow from operating activities was -₹1.30 crore, investing activities was -₹81.26 crore and financing activities was ₹115.18 crore. The filing did not provide year-earlier H1 cash-flow figures for comparison. Capital expenditure was ₹0 crore for the period.
| ₹ crore | As of 30 September 2026 |
|---|---|
| Total assets | 226.21 |
| Total equity | 204.35 |
| Borrowings | 0 |
| Cash and equivalents | 75.05 |
| Inventories | 0 |
| Trade receivables | 2.74 |
Source: Company's results filing (XBRL).
| ₹ crore | H1 FY27 |
|---|---|
| Cash from operations | −1.30 |
| Cash from investing | −81.26 |
| Cash from financing | 115.18 |
| Capital expenditure | 0 |
Source: Company's results filing (XBRL).
How did other Pharmaceuticals companies do?
The comparison covered 65 other Pharmaceuticals companies that had filed for the quarter as of 5 November 2026. Their median revenue growth was 18.9%. The available peer data do not state how many of these companies grew slower than Transchem or faster than Transchem.
Among the 60 Pharmaceuticals peers for which profit was compared, 43 reported higher profit. The peer data do not provide Transchem’s own revenue growth percentage, so the slower-growth and faster-growth counts cannot be stated from the supplied figures.
| Transchem revenue growth (YoY) | not comparable |
|---|---|
| Median of 65 other Pharmaceuticals companies | +18.9% |
| Companies whose net profit rose | 43 of 60 |
Source: Filed results (XBRL) of the industry's companies.
Quick answers
What was Transchem's revenue in Q2 FY27?
Revenue from operations was ₹0.93 crore (consolidated).
Did Transchem make a profit in Q2 FY27?
Yes. Net profit was ₹2.05 crore.
What was Transchem's EPS in Q2 FY27?
Basic earnings per share were ₹1.68.
When did Transchem announce its Q2 FY27 results?
On 4 November 2026, in a filing to the BSE.
Sources
How this was written: every figure in the tables and charts is calculated from the company’s filed results (XBRL) and MarketPing’s price measurements. The text is drafted with AI from those figures and the filings, and a checker removes any sentence carrying a number it cannot trace to them. How we write these.
This is information, not investment advice. MarketPing does not recommend buying or selling any security.